What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Sell
38
CARA Quote, Financials, Valuation and Earnings
Last price:
$5.57
Seasonality move
:
-6.21%
Day range:
$5.42 - $5.58
52-week range:
$2.71 - $11.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.46x
P/B ratio:
33.04x
Volume:
4.2K
Avg. volume:
13.9K
1-year change:
-44.96%
Market cap:
$24.8M
Revenue:
$7.1M
EPS (TTM):
-$15.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
$1.6M | -$2.94 | -73.37% | -83.05% | $12.00 |
|
ADMA
ADMA Biologics
|
$112.8M | $0.15 | 42.17% | 75% | $25.27 |
|
NURO
NeuroMetrix
|
-- | -- | -- | -- | -- |
|
OCGN
Ocugen
|
$300K | -$0.05 | -100% | -- | $6.75 |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.22 | 16.58% | -42.86% | $17.45 |
|
TGTX
TG Therapeutics
|
$100.7M | $0.20 | 84.44% | -95.36% | $42.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
$5.42 | $12.00 | $24.8M | -- | $0.00 | 0% | 3.46x |
|
ADMA
ADMA Biologics
|
$20.22 | $25.27 | $4.8B | 24.66x | $0.00 | 0% | 11.52x |
|
NURO
NeuroMetrix
|
$4.45 | -- | $9.1M | -- | $0.00 | 0% | 2.06x |
|
OCGN
Ocugen
|
$0.71 | $6.75 | $208.7M | -- | $0.00 | 0% | 47.76x |
|
OCUL
Ocular Therapeutix
|
$7.53 | $17.45 | $1.2B | -- | $0.00 | 0% | 18.70x |
|
TGTX
TG Therapeutics
|
$42.80 | $42.83 | $6.7B | 305.71x | $0.00 | 0% | 20.38x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
-- | -3.732 | -- | 10.67x |
|
ADMA
ADMA Biologics
|
17.17% | 4.789 | 1.78% | 2.76x |
|
NURO
NeuroMetrix
|
-- | 0.088 | -- | 12.38x |
|
OCGN
Ocugen
|
49.18% | 4.395 | 12.22% | 2.71x |
|
OCUL
Ocular Therapeutix
|
17.85% | 3.384 | 5.09% | 10.26x |
|
TGTX
TG Therapeutics
|
52.36% | 3.612 | 5.21% | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CARA
Cara Therapeutics
|
$1.5M | -$5.5M | -374.56% | -374.56% | -374.98% | -$4M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
NURO
NeuroMetrix
|
$312K | -$1.7M | -41.7% | -41.7% | -296.61% | -$1.8M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
Cara Therapeutics vs. Competitors
-
Which has Higher Returns CARA or ADMA?
ADMA Biologics has a net margin of -527.77% compared to Cara Therapeutics's net margin of 95.19%. Cara Therapeutics's return on equity of -374.56% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About CARA or ADMA?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 121.61%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 24.99%. Given that Cara Therapeutics has higher upside potential than ADMA Biologics, analysts believe Cara Therapeutics is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 ADMAADMA Biologics4 0 0 -
Is CARA or ADMA More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.
-
Which is a Better Dividend Stock CARA or ADMA?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or ADMA?
Cara Therapeutics quarterly revenues are $1.5M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Cara Therapeutics's net income of -$7.7M is lower than ADMA Biologics's net income of $111.9M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 24.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.46x versus 11.52x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.46x -- $1.5M -$7.7M ADMAADMA Biologics11.52x 24.66x $117.5M $111.9M
-
Which has Higher Returns CARA or NURO?
NeuroMetrix has a net margin of -527.77% compared to Cara Therapeutics's net margin of -256.8%. Cara Therapeutics's return on equity of -374.56% beat NeuroMetrix's return on equity of -41.7%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M NURONeuroMetrix53.12% -$0.75 $16M -
What do Analysts Say About CARA or NURO?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 121.61%. On the other hand NeuroMetrix has an analysts' consensus of -- which suggests that it could grow by 8888.76%. Given that NeuroMetrix has higher upside potential than Cara Therapeutics, analysts believe NeuroMetrix is more attractive than Cara Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 NURONeuroMetrix0 0 0 -
Is CARA or NURO More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison NeuroMetrix has a beta of 2.153, suggesting its more volatile than the S&P 500 by 115.333%.
-
Which is a Better Dividend Stock CARA or NURO?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroMetrix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. NeuroMetrix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or NURO?
Cara Therapeutics quarterly revenues are $1.5M, which are larger than NeuroMetrix quarterly revenues of $587.3K. Cara Therapeutics's net income of -$7.7M is lower than NeuroMetrix's net income of -$1.5M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while NeuroMetrix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.46x versus 2.06x for NeuroMetrix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.46x -- $1.5M -$7.7M NURONeuroMetrix2.06x -- $587.3K -$1.5M
-
Which has Higher Returns CARA or OCGN?
Ocugen has a net margin of -527.77% compared to Cara Therapeutics's net margin of -1816.75%. Cara Therapeutics's return on equity of -374.56% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About CARA or OCGN?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 121.61%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 844.45%. Given that Ocugen has higher upside potential than Cara Therapeutics, analysts believe Ocugen is more attractive than Cara Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 OCGNOcugen2 0 0 -
Is CARA or OCGN More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.
-
Which is a Better Dividend Stock CARA or OCGN?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or OCGN?
Cara Therapeutics quarterly revenues are $1.5M, which are larger than Ocugen quarterly revenues of $764K. Cara Therapeutics's net income of -$7.7M is higher than Ocugen's net income of -$13.9M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.46x versus 47.76x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.46x -- $1.5M -$7.7M OCGNOcugen47.76x -- $764K -$13.9M
-
Which has Higher Returns CARA or OCUL?
Ocular Therapeutix has a net margin of -527.77% compared to Cara Therapeutics's net margin of -283.27%. Cara Therapeutics's return on equity of -374.56% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About CARA or OCUL?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 121.61%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.45 which suggests that it could grow by 131.8%. Given that Ocular Therapeutix has higher upside potential than Cara Therapeutics, analysts believe Ocular Therapeutix is more attractive than Cara Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 OCULOcular Therapeutix5 0 0 -
Is CARA or OCUL More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.685%.
-
Which is a Better Dividend Stock CARA or OCUL?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or OCUL?
Cara Therapeutics quarterly revenues are $1.5M, which are smaller than Ocular Therapeutix quarterly revenues of $17.1M. Cara Therapeutics's net income of -$7.7M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.46x versus 18.70x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.46x -- $1.5M -$7.7M OCULOcular Therapeutix18.70x -- $17.1M -$48.4M
-
Which has Higher Returns CARA or TGTX?
TG Therapeutics has a net margin of -527.77% compared to Cara Therapeutics's net margin of 21.57%. Cara Therapeutics's return on equity of -374.56% beat TG Therapeutics's return on equity of 12.81%.
Company Gross Margin Earnings Per Share Invested Capital CARACara Therapeutics70.96% -$1.73 -$4.6M TGTXTG Therapeutics85.77% $0.15 $466.8M -
What do Analysts Say About CARA or TGTX?
Cara Therapeutics has a consensus price target of $12.00, signalling upside risk potential of 121.61%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 0.08%. Given that Cara Therapeutics has higher upside potential than TG Therapeutics, analysts believe Cara Therapeutics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CARACara Therapeutics0 1 0 TGTXTG Therapeutics5 0 0 -
Is CARA or TGTX More Risky?
Cara Therapeutics has a beta of 0.499, which suggesting that the stock is 50.057% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.
-
Which is a Better Dividend Stock CARA or TGTX?
Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CARA or TGTX?
Cara Therapeutics quarterly revenues are $1.5M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Cara Therapeutics's net income of -$7.7M is lower than TG Therapeutics's net income of $23.3M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 305.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 3.46x versus 20.38x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CARACara Therapeutics3.46x -- $1.5M -$7.7M TGTXTG Therapeutics20.38x 305.71x $108.2M $23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 2.14% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 3.3% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 2.17% over the past day.
